Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 1435Pancreatic Neoplasms 856Carcinoma, Hepatocellular 742Stomach Neoplasms 648Colonic Neoplasms 446Rectal Neoplasms 406Esophageal Neoplasms 399Breast Neoplasms 330Carcinoma, Non-Small-Cell Lung 328Neoplasms 307Liver Neoplasms 283Cholangiocarcinoma 244Ovarian Neoplasms 241Lung Neoplasms 239Neoplasm Metastasis 237Gastrointestinal Neoplasms 219Melanoma 185Esophageal Squamous Cell Carcinoma 166Prostatic Neoplasms 165Biliary Tract Neoplasms 161Endometrial Neoplasms 142Squamous Cell Carcinoma of Head and Neck 129Uterine Cervical Neoplasms 128Head and Neck Neoplasms 113Carcinoma, Renal Cell 113Sarcoma 101Urinary Bladder Neoplasms 97Adenocarcinoma Of Esophagus 90Triple Negative Breast Neoplasms 86Anus Neoplasms 83

Interventions

Gemcitabine 3130-nm albumin-bound paclitaxel 2Taxes 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × Gastrointestinal × 1 year × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT05630183 2025-11-13

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Agenus Inc.

Phase 2 Active not recruiting
81 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡